415 related articles for article (PubMed ID: 25595344)
1. Imaging biomarkers in prostate cancer: role of PET/CT and MRI.
Picchio M; Mapelli P; Panebianco V; Castellucci P; Incerti E; Briganti A; Gandaglia G; Kirienko M; Barchetti F; Nanni C; Montorsi F; Gianolli L; Fanti S
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):644-55. PubMed ID: 25595344
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view.
Schiavina R; Brunocilla E; Borghesi M; Vagnoni V; Castellucci P; Nanni C; Ceci F; Gacci M; Martorana G; Fanti S
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):310-3. PubMed ID: 23933383
[TBL] [Abstract][Full Text] [Related]
3. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis.
Treglia G; Ceriani L; Sadeghi R; Giovacchini G; Giovanella L
Clin Chem Lab Med; 2014 May; 52(5):725-33. PubMed ID: 24310773
[TBL] [Abstract][Full Text] [Related]
4. [¹¹C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Incerti E; Mapelli P; Kirienko M; Briganti A; Gandaglia G; Montorsi F; Gianolli L; Picchio M
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):877-84. PubMed ID: 25697127
[TBL] [Abstract][Full Text] [Related]
5. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
[TBL] [Abstract][Full Text] [Related]
8. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
9. Choline PET/CT for prostate cancer: main clinical applications.
Fuccio C; Rubello D; Castellucci P; Marzola MC; Fanti S
Eur J Radiol; 2011 Nov; 80(2):e50-6. PubMed ID: 20800404
[TBL] [Abstract][Full Text] [Related]
10. How does endorectal MRI, PET-CT and transrectal ultrasound contribute to diagnosis and management of localized prostate cancer.
Rincón Mayans A; Diaz-Tejeiro BZ; Rioja Zuazu J; Díaz Dorronsoro L; Rodriguez Fraile M; Boillos AB; Bergera JZ
Arch Esp Urol; 2011 Oct; 64(8):746-64. PubMed ID: 22052757
[TBL] [Abstract][Full Text] [Related]
11. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
12. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
Marzola MC; Chondrogiannis S; Ferretti A; Grassetto G; Rampin L; Massaro A; Castellucci P; Picchio M; Al-Nahhas A; Colletti PM; Marcolongo A; Rubello D
Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
[TBL] [Abstract][Full Text] [Related]
13. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
Calabria F; Chiaravalloti A; Tavolozza M; Ragano-Caracciolo C; Schillaci O
Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
[TBL] [Abstract][Full Text] [Related]
15. [Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment].
Cochet A; Kanoun S; Humbert O; Walker PM; Cormier L; Créhange G; Brunotte F
Cancer Radiother; 2014 Oct; 18(5-6):509-16. PubMed ID: 25195114
[TBL] [Abstract][Full Text] [Related]
16. Value of bimodal (18)F-choline-PET/MRI and trimodal (18)F-choline-PET/MRI/TRUS for the assessment of prostate cancer recurrence after radiation therapy and radical prostatectomy.
Paparo F; Piccardo A; Bacigalupo L; Romagnoli A; Piccazzo R; Monticone M; Cevasco L; Campodonico F; Conzi GM; Carmignani G; Rollandi GA
Abdom Imaging; 2015 Aug; 40(6):1772-87. PubMed ID: 25579170
[TBL] [Abstract][Full Text] [Related]
17. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
18. Incidental diagnosis of a PSA-negative prostate cancer by 18FDG PET/CT in a patient with hypopharyngeal cancer.
Bucerius J; Ahmadzadehfar H; Hortling N; Joe AY; Palmedo H; Biersack HJ
Prostate Cancer Prostatic Dis; 2007; 10(3):307-10. PubMed ID: 17353915
[TBL] [Abstract][Full Text] [Related]
19. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer.
Castellucci P; Fuccio C; Marzola MC; Al-Nahhas A; Rubello D; Fanti S
Nucl Med Commun; 2011 Jun; 32(6):475-8. PubMed ID: 21394046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
